Kenneth Kovan
Founder bij BIOVAXYS TECHNOLOGY CORP.
Vermogen: 411 760 $ op 31-03-2024
Profiel
Kenneth E.
Kovan is the founder of AVAX Technologies, Inc. (founded in 1990).
Mr. Kovan is also the founder of BioVaxys Technology Corp., BioVaxys LLC.
Mr. Kovan's current job(s) include President at Chaperone Technologies, Inc. and Managing Principal & Owner at Bingham Hill Ventures.
Mr. Kovan's former job(s) include Principal at Thomas Jefferson University, GSK Plc, and Wyeth-Ayerst Research, and Partner at Horizon Discovery Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOVAXYS TECHNOLOGY CORP
5.07% | 26-01-2024 | 7 352 862 ( 5.07% ) | 411 760 $ | 31-03-2024 |
Actieve functies van Kenneth Kovan
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Founder | - |
Chaperone Technologies, Inc.
 Chaperone Technologies, Inc. Medical SpecialtiesHealth Technology Chaperone Technologies, Inc. develops novel products for infectious diseases. The firm develops and produces peptide-based antimicrobial products to treat infectious diseases. The company was founded by Michael and Elisabeth Lang in March 2014 and is headquartered in Bogart, GA. | President | - |
BioVaxys LLC
 BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Founder | - |
| Bingham Hill Ventures | Corporate Officer/Principal | - |
Eerdere bekende functies van Kenneth Kovan
| Bedrijven | Functie | Einde |
|---|---|---|
Horizon Discovery Ltd.
 Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
| Wyeth-Ayerst Research | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
| Thomas Jefferson University | Corporate Officer/Principal | - |
| AVAX TECHNOLOGIES, INC. | Founder | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| AVAX TECHNOLOGIES, INC. | Health Technology |
| GSK PLC | Health Technology |
| BIOVAXYS TECHNOLOGY CORP. | Non-Energy Minerals |
| Bedrijven in privébezit | 5 |
|---|---|
| Wyeth-Ayerst Research | |
Chaperone Technologies, Inc.
Chaperone Technologies, Inc. Medical SpecialtiesHealth Technology Chaperone Technologies, Inc. develops novel products for infectious diseases. The firm develops and produces peptide-based antimicrobial products to treat infectious diseases. The company was founded by Michael and Elisabeth Lang in March 2014 and is headquartered in Bogart, GA. | Health Technology |
BioVaxys LLC
BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Health Technology |
| Bingham Hill Ventures | |
Horizon Discovery Ltd.
Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
